Further in vivo experiments on a colitis model induced by dextran sodium sulfate showed that 10 was more effective in minimizing weight loss and colon tissue damage than the RIPK2 inhibitor WEHI-345 and the Janus tyrosine kinase (JAK) inhibitor filgotinib (approved in the United Kingdom for the treatment of UC). This evidence concerns the gene RIPK2 and colitis.